Wardwizard Healthcare Limited Closes ₹2.72 Crore Warrant Issue

Wardwizard Healthcare Limited closed a ₹2.7175 crore transaction on November 4, 2026, issuing 10.87 million fully convertible warrants at ₹2.50 each. The transaction adds to the company's ongoing capital restructuring and fundraising activity, which has included a separate shareholder-approved warrant proposal and an increase in authorised share capital during 2026.

What did Wardwizard Healthcare close on November 4?

Wardwizard Healthcare closed the issuance of 10,870,000 fully convertible warrants at an issue price of ₹2.50 per warrant, according to the transaction details provided. The issue generated gross proceeds of ₹2.7175 crore, calculated as 10.87 million warrants multiplied by the stated issue price.

Fully convertible warrants give their holders the right to receive equity shares after conversion under the terms governing the instrument. The supplied transaction information identifies the number of warrants, issue price, gross proceeds and closing date, but does not specify the allottees, conversion period, conversion conditions or the intended use of these particular proceeds.

The closure is relevant because it represents a completed capital-raising event rather than only a board proposal or shareholder approval. It also comes as Wardwizard Healthcare has been increasing its financial flexibility while reporting losses and without a dividend plan, as described in its FY2025-26 annual-report-related disclosures.

How does this issue compare with the August warrant proposal?

The November transaction differs in size and pricing from Wardwizard Healthcare's preferential warrant proposal approved on August 31, 2026. In that proposal, the company approved up to 12.5 million fully convertible warrants at ₹10 each, with aggregate proceeds of up to ₹12.5 crore.

The August proposal stated that each warrant could be converted into one equity share with a face value of ₹10 within 18 months of allotment. Warrants not converted within that period would lapse, and the amount paid would be forfeited. Those terms were reported in connection with the August approval and should not be assumed to apply to the November 4 transaction, for which such terms were not provided.

Promoters Yatin Sanjay Gupte and Sheetal Mandar Bhalerao were among the proposed allottees under the August proposal. Gupte was allotted 5.2 million warrants and Bhalerao 1.8 million, while 16 non-promoter entities were also proposed allottees. The available November transaction information does not identify whether the closed issue relates to those proposed allocations.

Why had Wardwizard Healthcare increased its authorised capital?

Wardwizard Healthcare's shareholders considered an increase in authorised share capital from ₹7.5 crore to ₹25 crore as part of the company's 42nd annual general meeting process. The AGM was held through video conference on September 30, 2026, and the company adopted its audited FY2025-26 financial statements alongside resolutions involving directors, the statutory auditor, convertible warrants and related-party transactions.

Authorised share capital sets the maximum nominal value of shares a company may issue under its constitutional and regulatory framework. Raising this limit does not itself issue new shares or warrants, but it can provide capacity for future equity-linked capital raising, subject to the applicable approvals and terms.

The company had linked its August warrant proposal with growth, expansion, working capital and investments in group entities, including Wardwizard Medicare Private Limited. Its disclosures described a broader effort to arrange capital while pursuing expansion in healthcare operations and activities for Ayurveda practitioners.

What did the company disclose about funds for Wardwizard Medicare?

A corrigendum to the 42nd AGM notice, issued on September 19, 2026, clarified the planned use of ₹8 crore from a proposed preferential issue. Wardwizard Healthcare stated that the full ₹8 crore would be invested exclusively in Wardwizard Medicare Private Limited through subscriptions to 2% non-cumulative convertible preference shares.

The stated purpose of that investment was growth and expansion of Wardwizard Medicare's hospital business. Wardwizard Healthcare also said that no part of the specified preferential-issue proceeds would be used for another promoter or promoter-group company.

The corrigendum further said that the funds would not be used, directly or indirectly, to repay loans, advances, financial assistance, dues or other obligations of Wardwizard Medicare or any other related party. This disclosure relates to the proposed preferential issue described in the AGM documentation; the supplied November 4 transaction details do not provide a separate use-of-proceeds allocation.

How could the warrant activity matter to shareholders and the market?

Warrant issues can affect the shareholding structure when holders convert them into equity shares. For the August proposal, Wardwizard Healthcare indicated that Yatin Sanjay Gupte's post-conversion stake could increase to 41.51% and Sheetal Mandar Bhalerao's to 14.40%, while the non-promoter group could hold 27.09%. These figures relate specifically to that proposed issue.

For existing shareholders, any future equity conversion can increase the number of outstanding shares and may dilute ownership percentages for holders who do not participate. The scale of the effect depends on the final number of shares issued, conversion timing and the company's equity base. The November transaction provides no conversion schedule or post-conversion shareholding data, so its eventual dilution effect cannot be quantified from the available information.

Wardwizard Healthcare's share price was ₹45.34 as of 5:43 on November 4, 2026, according to the supplied market data. That market price is separate from the ₹2.50 warrant issue price. The information provided does not attribute any share-price movement to the transaction or provide a company outlook on operating improvement.

Conclusion

Wardwizard Healthcare's completed issuance of 10.87 million fully convertible warrants at ₹2.50 each raised gross proceeds of ₹2.7175 crore on November 4. The transaction sits alongside a wider set of 2026 capital actions, including the proposed ₹12.5 crore warrant issue, a rise in authorised share capital to ₹25 crore and planned funding for Wardwizard Medicare.

The next important disclosures will be the terms and allottee details for the November transaction, including any conversion conditions and use of proceeds. Investors will also watch progress on the previously disclosed hospital-expansion investment in Wardwizard Medicare and the execution of the August warrant proposal within its stated 18-month conversion window.